Senior Partner, PureTech Health
Dr. John L. LaMattina is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. He retired from this position in December 2007.
Dr. LaMattina spent 30 years at Pfizer Inc having joined as a medicinal chemist in 1977. Over the years, he held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999.
Dr. LaMattina graduated cum laude from Boston College in 1971 with a B.S. in Chemistry. He attended the University of New Hampshire receiving a Ph.D. in Organic Chemistry in 1975. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor.
During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis, and AIDS. Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?” He is also a contributor to Forbes.com.
Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.
Dr. LaMattina is a Senior Partner and a member of the Board of Directors of PureTech Health. He serves on the Board of Directors of Ligand Pharmaceuticals, Zafgen, Gelesis, Immunome and Vedanta. Dr. LaMattina also serves as a Trustee Associate for Boston College.
Dr. LaMattina lives in Stonington, Connecticut, with his wife, Mary. They have three children. He has had a long history of community activities most recently serving as President of the Board of Trustees of the Terri Brodeur Breast Cancer Foundation and the Board of Trustees of the Community Foundation of Eastern Connecticut.
Executive Director Venture Development, Uconn
Mostafa Analoui, Ph.D., is Executive Director of Venture Development and Technology Incubation Program (TIP) at UConn. Previously, he was Head of Healthcare and Life Sciences at Livingston Securities (New York, NY) with investment focus in private and public companies in biotech, medtech and healthcare services. Prior to that, he was the Senior Director at Pfizer Global Research and Development. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies.
While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.
In addition to industry leadership in biomedical and technology fields, he consults and lectures in US, Europe and Asia. He has also served on various scientific, regulatory, and business advisory committees and boards, including NIH, NSF, PhRMA, NASA, and OECD. Dr. Analoui has authored over 130 publications, including journal articles, a book and book chapters and technical reports. Dr. Analoui is currently Adjust Professor at University of Connecticut (Storrs/Farmington, CT), Brown University (Providence, RI), and Northeastern University (Boston, MA). He is also senior member of IEEE, SPIE, and RSNA.
He was Chairman of the Board of VirtualScopics (Nasdaq: VSCP) and currently serves as Chairman of the Board member of Cyclica (Chairman), Connecticut Innovations, and NanoBusiness Commercialization Association.
Attorney, Pullman & Comley LLC
Russell Anderson’s business and technology practice focuses on assisting clients accomplish “what’s next” – whether “next” is a new mobile app, marketing campaign or medical device. In particular, Russ has expertise helping clients in the software, e-commerce, marketing, market research, healthcare and biotechnology industries. Russ excels at partnering with clients, frequently in the role of outside general counsel, to help them achieve their goals. Russ is a Member in Pullman & Comley’s Business and Finance practice.
His general business practice includes representing clients in the structure and consummation of mergers and acquisitions, joint venture, and financing transactions. Additionally, he is experienced in both for-profit and nonprofit corporate governance matters.
Russ previously served as outside governmental affairs counsel to the largest trade group for market research businesses in the United States, and continues to participate as a regular presenter to the Insights Association’s General Counsel Forums. Russ has significant expertise representing a wide range of firms in the market research industry, such as custom and syndicated market research, data analytics and panel providers.
Russ also represents pharmaceutical, medical device, and mobile health-related entities. As outside general counsel to a pharmaceutical contract manufacturer, Russ drafted and negotiated numerous contracts common in the pharmaceutical industry, such as product development arrangements and commercial supply agreements. Russ also represents health care providers, including physicians, hospitals and home health care agencies, on matters relating to contracts, accreditation, licensure and Medicare/Medicaid.
As Russ counsels clients that collect and use large amounts of personal data, he understands the expansive web of state, federal and international privacy and data protection regulations, including questions regarding privacy policies and procedures; security breaches; HIPAA and HITECH; cross-border data transfers and processing (including GDPR compliance and EU Privacy Shield certification); and email and telemarketing regulation.
Chief Medical Officer, Vireo Health
Dr. Stephen M. Dahmer is a board-certified family physician whose passion for health and healing has taken him around the globe. A fellow of the Arizona Center for Integrative Medicine, for over two decades he has studied the relationships between plants and people, working closely with diverse cultures and documenting their uses of plants and other integrative therapies.
Aspiring to understand ethnomedical systems, as well as the plants and traditional beliefs that support them, Dr. Dahmer has worked in divergent settings including Umbanda terreiros in the heart of Brazil’s second largest slum, Maori clinics in New Zealand, native healers on the Palauan Islands, and as a hospitalist to the Navajo (Dine) Tribe in Chinle, Arizona.
Since 2015, Dr. Dahmer has served as Chief Medical Officer of Vireo Health, a physician-founded, patient-focused company dedicated to providing best-in-class cannabis-based products and unrivaled care. For Vireo Health, he oversees clinical research partnerships, physician outreach and engagement, and over 100 employees providing education, support, awareness and a compassionate patient experience to tens of thousands of patients utilizing medical cannabis.
Dr. Dahmer is Assistant Clinical Professor of Family Medicine and Community Health at the Icahn School of Medicine at Mount Sinai and continues to practice Family Medicine in New York.
Partner, Assurance Services, Marcum LLP
Lisa Delfini is a partner in the Firm’s New Haven office. She has over 24 years of experience in both public accounting and private industry, including 17 years auditing companies of all sizes. Her experience includes companies in the pharma, high-tech, consumer products, manufacturing, real estate, investment management and grocery distribution industries. In her current role, she provides controllership and CFO services to both public and private companies.
Prior to joining Marcum, Lisa was a global controller for four years at a Fortune 50 multinational corporation. In her first role there, she served as a technical advisor to the principal accounting officer, consulting with the industrial business controllers on complex and subjective accounting matters. In addition, she set accounting policies and procedures, prepared and reviewed SEC financial statements and disclosures, and conducted training courses. In her second role there, she was the controller of a division with $4B in annual revenues and over 120 locations around the globe. During this time, Ms. Delfini was responsible for all aspects of financial reporting, supervising a team of 30, and provided strategic leadership to industrial an ERP implementation at all North American and European locations.
Previously, Ms. Delfini was a partner at a global firm, working in several different roles, including leading audit engagements, serving as an engagement quality reviewer, publishing accounting publications and consulting on technical accounting matters in the firm's national Department of Professional Practice. In addition, Ms. Delfini was a partner in the SEC Services Group, reviewing SEC filings for annual and quarterly reports, and public offerings of debt and equity, and helping clients have productive and efficient correspondence with the SEC. She took an international assignment in Birmingham, U.K. in 1994.
Ms. Delfini also was a manager of finance at a manufacturing company in New Haven, CT.
Attorney, Pullman & Comley LLC
Nancy Hancock’s business law and corporate finance practice encompasses technology, tax, venture capital, securities and e-commerce. Business owners and management rely on Nancy’s substantive expertise in numerous fields in representing them. Her clients include entrepreneurs, companies financed with venture capital, and family-owned enterprises. Their varied businesses have included not only businesses in metal bending, casting and plating; crucible manufacturing; and industrial components design, manufacture and distribution; but also marketing, private equity, hedge funds; and investment portfolio management. Nancy develops and negotiates the terms of software licenses, enterprise application software agreements and IT consulting and service agreements. Her bricks and mortar background in drafting and negotiating commercial contracts has translated well into making her a capable solutions provider for sophisticated business problems.
Nancy negotiates acquisitions, divestitures and strategic alliances and licenses involving traditional and technology-based businesses. Her work includes guiding companies through acquisitive and divisive reorganizations, drafting shareholders agreements, providing tax-based advice for business structures, and securities law compliance.
As a company counselor, Nancy brings her clients the benefit of her broad experience. She advises boards of directors and business managers on more than just corporate governance, but also the practical ramifications of their choices. She writes comprehensible business forms for protecting and licensing technology and software and for the sale of goods and services. She works with clients to create and negotiate contracts that are sensible, thorough and usable in the real world. She drafts and negotiates intellectual property licenses, web hosting agreements, contact licensing, technology escrows and intellectual property-based financing documents. She prepares proprietary information protection and noncompetition agreements for technology-based businesses. She is versed in the protection and exploitation of the assets of fast-growth companies. Technical consultants, analysts and application service providers also rely on Nancy’s skills.
Nancy has been recognized as a leader at the firm. As a member of the firm’s Executive Committee, she brings firsthand understanding to the C-level executives she often advises. She also chairs several of the firm’s specific practice areas, including the Emerging Business and Venture Capital Practice, as well as the firm’s Intellectual Property and Technology Practice. As a member of the firm’s Corporate Transactions and Securities practices, she guides privately-held businesses through their critical generational control and tax planning processes. As an active member of the firm’s Tax Practice, Nancy has litigated and negotiated business valuations with the Internal Revenue Service. She works with her clients’ internal accounting staff and outside auditors to coordinate business and tax planning goals seamlessly. Nancy represents investment advisers, commodity pool operators, broker-dealers and other securities professionals and advises them on compliance with state and federal securities laws. She has experience in dealing with complex fixed and equity financial products and securitized debt portfolios. She is also active in the firm’s Commercial Finance practice, representing borrowers and lenders alike.
Founder & CEO of FDHint, LLC
Florence D. Hudson is Founder & CEO of FDHint, LLC consulting in advanced technologies and diversity & inclusion. Her advanced technology expertise includes artificial intelligence, blockchain, connected healthcare, cybersecurity, big data, internet of things, and smart cities. Formerly IBM Vice President and Chief Technology Officer, Internet2 Senior Vice President and Chief Innovation Officer, and an aerospace engineer at Grumman and NASA, she is Special Advisor for the NSF Cybersecurity Center of Excellence at Indiana University, and Northeast Big Data Innovation Hub at Columbia University. She serves on Boards for Princeton University, Cal Poly San Luis Obispo, Stony Brook University, and Union County College. She is co-founder of IEEE-ISTO Blockchain in Healthcare Global, and on the Editorial Board for Blockchain in Healthcare Today. She graduated from Princeton University with a BSE in Mechanical and Aerospace Engineering, and attended executive education at Harvard Business School and Columbia University.
Partner, Marcum LLP
Michael Lenkowski is a partner in the Tax & Business Services group. He has more than 15 years of experience in public accounting. Mr. Lenkowski specializes in audit, tax, accounting services and transaction services for privately held businesses. His industry experience includes, but is not limited to, manufacturing, distribution, retail, construction, professional services, technology companies, and investment companies.
Mr. Lenkowski’s expertise in equity structure, equity awards, compensation, organizational planning, and succession planning helps address business’s needs by providing innovative and feasible strategies focused on compliance and tax savings. He also has extensive experience in mergers and acquisitions, due diligence, international operations, and reporting requirements in the U.S.
Founding Principal, Marinstein & Co.
Jeff Marinstein is an Instructor-in-Residence in the UConn School of Business. His work is focused on the business use and implementation of blockchains. He is the Founding Principal of Marinstein & Co. providing strategic consulting at the intersection of business and technology. For the past 25 years he has served both large enterprise and mid-market companies. Mr. Marinstein was the head of global strategy and product management within IBM Global Technology Services, and a Principal in the business strategy practice at Slalom Consulting. Prior to IBM he was the co-founder and President of Contingency Planning Research, a pioneer in the field of business continuity and risk management.
Attorney, Brenner, Saltzman & Wallman LLP
Wayne regularly advises clients on complex sale and development transactions including mergers and acquisitions, traditional, mezzanine and venture capital financing, strategic alliances, joint ventures and co-development projects and technology licensing. His clients include public and private companies, entrepreneurs and start-up businesses in a wide variety of industries such as, traditional and high tech manufacturing, new media, internet, professional services, and biotechnology. While his practice embraces all aspects of general business representation, he focuses on transactions where he can add or capture value for clients by crafting solutions that integrate business, financial, tax, accounting and legal considerations. Because many of the firm’s clients have tended to start as entrepreneurs in leading edge industries, he has a long history of addressing legal and business issues in emerging industries where there is little to no legal or business road map and many of the issues require creative and textured solutions.
Wayne has been a member of the board of directors of three publicly held companies and served on audit, compensation, and corporate governance committees. He co-founded the Connecticut Nanotechnology Initiative and served on the State of Connecticut Nanotechnology Advisory Panel until 2010. Wayne has lectured on legal and business issues involving strategic alliances, venture capital, accounting, nanotechnology, and the internet. He received his B.A., cum laude, from American University and his J.D., with honors, from the University of Connecticut School of Law. Wayne is a member of the Connecticut Bar.
Partner, Shipman & Goodwin LLP
Matthew Monteith is a partner in the firm's Business and Finance Practice Group, where he has a broad transactional practice. He represents venture capital and private equity firms in connection with portfolio company investments, acquisitions and dispositions and other debt and equity financings. Matt regularly helps to form, finance and advise high-growth companies in the software, mobile application, pharmaceutical and biotechnology, cybersecurity, consumer products and financial services industries through all stages of their growth.
Matt also represents commercial banks, mezzanine lenders, other senior and junior lending institutions, as well as corporate borrowers, in connection with
complex commercial finance transactions including term and revolving credit facilities, asset-based financings, acquisition and equipment financings
and mezzanine debt transactions.
Prior to joining Shipman & Goodwin, Matt spent a year at Connecticut Innovations, Incorporated, the State of Connecticut's venture capital fund focused on technology investing and innovation, where he assisted in structuring, negotiating and closing portfolio company investments.
Matt is a frequent presenter on issues relating to entity formation, convertible debt, preferred equity investment and commercial lending. He has been listed as a Connecticut Super Lawyer “Rising Star” each year since 2013.
Managing Partner, Fairview Capital Partners
Dr. Olofinboba is a Managing Partner at Fairview Capital Partners, a private equity investment management firm, and is involved in a broad set of investment, business development and governance activities at the firm. Additionally, he serves on the advisory boards of several private equity partnerships in Fairview’s fund portfolios.
Prior to joining Fairview, Dr. Olofinboba was a Consultant at McKinsey & Company, serving U.S. and global clients in healthcare and private equity. He has also practiced medicine as a board-certified internist/hospitalist and assistant professor at the University of Connecticut Health Center in Farmington, CT.
He is a director on the boards of the Connecticut Children’s Medical Center, the Connecticut Science Center, the National Association of Investment Companies (NAIC), and the Simsbury Bank & Trust Company, Inc.
Dr. Olofinboba received his medical degree from the University of Ibadan, Nigeria and an MBA in Financial Management from the MIT Sloan School of Management, where he was a Robert Toigo Fellow.
General Partner, Canaan Partners
Tim Shannon, MD, is a General Partner at Canaan Partners, a 31 year old early stage venture capital firm. Tim pairs his operating experience and medical background to create value for companies from the earliest stage through FDA approval. Prior to becoming an investor, Tim was president and chief executive officer of CuraGen, a publicly traded biopharmaceutical company focused on oncology. Before that he was SVP, Clinical Development, Bayer Healthcare. He began his career as a pulmonary and critical care physician at Yale. Tim did his post-graduate training at Harvard and Boston University, earned his medical degree from the University of Connecticut and has a B.A. in chemistry from Amherst College. Tim was the founding CEO of Arvinas (IPO, ARVN) and remains chairman. Tim was also a lead Series A investor in Civitas (acquired by Acorda), Novira (acquired by J&J), CytomX (IPO, CTMX), NextCure (IPO, NXTC), IDEAYA (IPO, IDYA). He currently is a director at NextCure, IDEAYA, Vivace, and RallyBio.
Executive Vice President and Chief Investment Officer, Connecticut Innovations
Dave is responsible for managing the investment function at CI, which includes staffing, portfolio and risk management, outreach, budget planning and performance measurement. He also is responsible for oversight of the Connecticut Bioscience Innovation Fund (CBIF) and the Regenerative Medicine Research Fund (RMRF).
When he joined CI in 2009 as senior managing director of investments, Dave had extensive senior-level experience in operations and finance, including more than 10 years as executive vice president, treasurer and CFO of CuraGen Corporation, a former CI portfolio company. Dave guided the biotech company through its initial public offering and helped raise more than $700 million. Dave was also involved in negotiating strategic and business development alliances with several pharmaceutical and biotech companies, including Roche, Bayer and Amgen-Freemont (Abgenix). He helped to grow CuraGen and its technology development subsidiary into an operation with more than 500 employees and a market capitalization as high as $5.3 billion.
Dave began his professional career with Coopers & Lybrand in Hartford, Connecticut (now part of PricewaterhouseCoopers), where he held various accounting and managerial positions.